Susan M. Ferguson

Susan M. Ferguson

Auto-generated profile, based on publicly available information

Susan M. Ferguson

Center for the Neurobiology of Addiction, Pain and Emotion University of Washington Seattle USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Neuroscience
Verified
Journal Article
Closed access
LYL.M. Yager
L.M. Yager
AGA.F. Garcia
A.F. Garcia
AWA.M. Wunsch
A.M. Wunsch
SFS.M. Ferguson
S.M. Ferguson

5 December 2010 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
SFSusan M Ferguson
Susan M Ferguson
DEDaniel Eskenazi
Daniel Eskenazi
MIMasago Ishikawa
Masago Ishikawa
MWMatthew J Wanat
Matthew J Wanat
PPPaul E M Phillips
Paul E M Phillips
JNJohn F Neumaier
John F Neumaier
The roles of striatopallidal (indirect) and striatonigral (direct) pathway neurons in regulating behavior is of great interest. Ferguson et al. selectively and transiently disrupt either one pathway or the other. They find that disrupting striatopallidal neuronal activity facilitated behavioral sensitization, whereas disrupting striatonigral neurons impaired its persistence. Dorsal striatum is important for the development of drug addiction; however, a precise understanding of the roles of striatopallidal (indirect) and striatonigral (direct) pathway neurons in regulating behaviors remains elusive. Using viral-mediated expression of an engineered G protein–coupled receptor (hM4D), we found that activation of hM4D receptors with clozapine-N-oxide (CNO) potently reduced striatal neuron excitability. When hM4D receptors were selectively expressed in either direct or indirect pathway neurons, CNO did not change acute locomotor responses to amphetamine, but did alter behavioral plasticity associated with repeated drug treatment. Specifically, transiently disrupting striatopallidal neuronal activity facilitated behavioral sensitization, whereas decreasing excitability of striatonigral neurons impaired its persistence. These findings suggest that acute drug effects can be parsed from the behavioral adaptations associated with repeated drug exposure and highlight the utility of this approach for deconstructing neuronal pathway contributions to behavior.

16 June 2020 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
ECElizabeth A. Crummy
Elizabeth A. Crummy
TOTimothy J. O’nEal
Timothy J. O’nEal
BBBritahny M. Baskin
Britahny M. Baskin
SFSusan M. Ferguson
Susan M. Ferguson
Substance use disorder (SUD) is a chronic, relapsing disease with a highly multifaceted pathology that includes (but is not limited to) sensitivity to drug-associated cues, negative affect, and motivation to maintain drug consumption. SUDs are highly prevalent, with 35 million people meeting criteria for SUD. While drug use and addiction are highly studied, most investigations of SUDs examine drug use in isolation, rather than in the more prevalent context of comorbid substance histories. Indeed, 11.3% of individuals diagnosed with a SUD have concurrent alcohol and illicit drug use disorders. Furthermore, having a SUD with one substance increases susceptibility to developing dependence on additional substances. For example, the increased risk of developing heroin dependence is twofold for alcohol misusers, threefold for cannabis users, 15-fold for cocaine users, and 40-fold for prescription misusers. Given the prevalence and risk associated with polysubstance use and current public health crises, examining these disorders through the lens of co-use is essential for translatability and improved treatment efficacy. The escalating economic and social costs and continued rise in drug use has spurred interest in developing preclinical models that effectively model this phenomenon. Here, we review the current state of the field in understanding the behavioral and neural circuitry in the context of co-use with common pairings of alcohol, nicotine, cannabis, and other addictive substances. Moreover, we outline key considerations when developing polysubstance models, including challenges to developing preclinical models to provide insights and improve treatment outcomes.

14 July 2004 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
ASAnne-Noël Samaha
Anne-Noël Samaha
NMNicolas Mallet
Nicolas Mallet
SFSusan M. Ferguson
Susan M. Ferguson
FGFrançois Gonon
François Gonon
TRTerry E. Robinson
Terry E. Robinson
The rapid delivery of drugs of abuse to the brain is thought to promote addiction, but why this occurs is unknown. In the present study, we characterized the influence of rate of intravenous cocaine infusion (5-100 sec) on three effects thought to contribute to its addiction liability: its ability to block dopamine (DA) uptake, to activate immediate early gene expression, and to produce psychomotor sensitization. Rapid infusions potentiated the ability of cocaine to block DA reuptake, to induce c-fosandarcmRNA expression, especially in mesocorticolimbic regions, and to produce psychomotor sensitization. Thus, the rate at which cocaine is delivered influences both its neurobiological impact and its ability to induce a form of drug experience-dependent plasticity implicated in addiction. We propose that rapidly delivered cocaine may be more addictive, in part, because this more readily induces forms of neurobehavioral plasticity that lead to the compulsive pursuit of drugs.

11 January 2006 in Neuropsychopharmacology
Verified
Journal Article
Closed access
SFSusan M Ferguson
Susan M Ferguson
SFStefania Fasano
Stefania Fasano
PYPengwei Yang
Pengwei Yang
RBRiccardo Brambilla
Riccardo Brambilla
TRTerry E Robinson
Terry E Robinson

10 July 2013 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
SFSusan M. Ferguson
Susan M. Ferguson
PPPaul E. M. Phillips
Paul E. M. Phillips
BRBryan L. Roth
Bryan L. Roth
JWJürgen Wess
Jürgen Wess
JNJohn F. Neumaier
John F. Neumaier
The dorsal striatum has been implicated in reward-based decision making, but the role played by specific striatal circuits in these processes is essentially unknown. Using cell phenotype-specific viral vectors to express engineered G-protein-coupled DREADD (designer receptors exclusively activated by designer drugs) receptors, we enhanced Gi/o- or Gs-protein-mediated signaling selectively in direct-pathway (striatonigral) neurons of the dorsomedial striatum in Long–Evans rats during discrete periods of training of a high versus low reward-discrimination task. Surprisingly, these perturbations had no impact on reward preference, task performance, or improvement of performance during training. However, we found that transiently increasing Gi/o signaling during training significantly impaired the retention of task strategies used to maximize reward obtainment during subsequent preference testing, whereas increasing Gs signaling produced the opposite effect and significantly enhanced the encoding of a high-reward preference in this decision-making task. Thus, the fact that the endurance of this improved performance was significantly altered over time—long after these neurons were manipulated—indicates that it is under bidirectional control of canonical G-protein-mediated signaling in striatonigral neurons during training. These data demonstrate that cAMP-dependent signaling in direct-pathway neurons play a well-defined role in reward-related behavior; that is, they modulate the plasticity required for the retention of task-specific information that is used to improve performance on future renditions of the task.